Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Common Equity (2017 - 2022)

Mesoblast's Common Equity history spans 6 years, with the latest figure at $497.0 million for Q2 2022.

  • For Q2 2022, Common Equity fell 14.51% year-over-year to $497.0 million; the TTM value through Jun 2022 reached $497.0 million, down 14.51%, while the annual FY2022 figure was $497.0 million, 14.51% down from the prior year.
  • Common Equity for Q2 2022 was $497.0 million at Mesoblast, down from $581.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $581.4 million in Q2 2021 and bottomed at $481.1 million in Q2 2019.
  • The 5-year median for Common Equity is $546.0 million (2018), against an average of $531.0 million.
  • The largest annual shift saw Common Equity rose 14.19% in 2020 before it dropped 14.51% in 2022.
  • A 5-year view of Common Equity shows it stood at $546.0 million in 2018, then decreased by 11.9% to $481.1 million in 2019, then grew by 14.19% to $549.3 million in 2020, then increased by 5.84% to $581.4 million in 2021, then dropped by 14.51% to $497.0 million in 2022.
  • Per Business Quant, the three most recent readings for MESO's Common Equity are $497.0 million (Q2 2022), $581.4 million (Q2 2021), and $549.3 million (Q2 2020).